Enovis (NYSE:ENOV) Shares Down 9.3% – Should You Sell?

Enovis Corporation (NYSE:ENOV)’s share price was down 9.3% during mid-day trading on Thursday . The company traded as low as $26.48 and last traded at $27.3720. Approximately 74,306 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 1,078,881 shares. The stock had previously closed at $30.18.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ENOV. Evercore set a $32.00 price objective on shares of Enovis in a research report on Monday, July 6th. UBS Group reaffirmed a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, July 6th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $41.86.

Enovis Trading Down 6.1%

The company has a market cap of $1.63 billion, a price-to-earnings ratio of -1.44 and a beta of 1.34. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The business’s fifty day simple moving average is $24.47 and its two-hundred day simple moving average is $23.93.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis Corporation will post 3.12 EPS for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired a total of 4,200 shares of company stock valued at $92,084 in the last three months. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. acquired a new position in Enovis during the second quarter worth approximately $291,000. Handelsbanken Fonder AB grew its position in shares of Enovis by 9.3% during the second quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock worth $437,000 after acquiring an additional 1,800 shares during the last quarter. Front Street Capital Management Inc. increased its holdings in shares of Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after acquiring an additional 384,124 shares during the period. Amundi increased its holdings in shares of Enovis by 2.3% in the 1st quarter. Amundi now owns 74,184 shares of the company’s stock valued at $1,688,000 after acquiring an additional 1,677 shares during the period. Finally, California State Teachers Retirement System raised its position in Enovis by 38.9% in the 1st quarter. California State Teachers Retirement System now owns 76,966 shares of the company’s stock valued at $1,751,000 after purchasing an additional 21,571 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.